Want to see SIBN full AI Analyst Report?
SIBN Stock Chart & Stats
$16.62
$0.43(2.59%)
At close: 4:00 PM EDT
$16.62
$0.43(2.59%)
Day’s Range― - ―
52-Week Range$11.48 - $21.89
Previous Close$17
Volume620.11K
Average Volume (3M)648.60K
Market Cap
$787.64M
Enterprise Value$453.48
Total Cash (Recent Filing)$144.68M
Total Debt (Recent Filing)$7.35M
Price to Earnings (P/E)―
Beta0.86
Next Earnings
Nov 09, 2026EPS Estimate
-0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.39
Shares Outstanding44,349,280
10 Day Avg. Volume524,959
30 Day Avg. Volume648,599
Financial Highlights & Ratios
PEG Ratio1.08
Price to Book (P/B)4.83
Price to Sales (P/S)4.27
P/FCF Ratio-94.40
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$24.50Price Target Upside47.41% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-0.43
Revenue Forecast (FY)$231.82M
Bulls Say, Bears Say
Bulls Say
High Gross MarginsSustained ~79–80% gross margins reflect strong per-procedure unit economics for iFuse implants and related tools. High gross margins provide durable operating leverage, allowing profitable scale as procedure volume grows and helping absorb modest price or mix pressure over the medium term.
Improving Profitability And Cash FlowMaterial improvement in adjusted EBITDA and a shift to positive trailing operating cash flow indicate the business is moving toward sustainable profitability. This reduces financing dependence and supports continued investment in commercialization and R&D while margins convert higher procedure volumes into operating cash.
Scalable Commercial FootprintA productive, expanding territory-based salesforce with strong revenue per territory demonstrates repeatable commercial scalability. Adding near-term territories is a low-friction way to expand surgeon adoption and procedure volume, supporting durable revenue growth as new products and reimbursement tailwinds arrive.
Bears Say
GAAP Profitability Still NegativeDespite margin and EBITDA progress, persistent GAAP losses (TTM net margin ~-8.1%) mean returns remain negative and equity returns are suppressed. Continued GAAP losses can limit flexibility for dividend or buybacks and require management to balance growth investment against a credible path to sustained GAAP profitability.
Negative Free Cash Flow And Investment-driven VariabilityThe business still consumes free cash after investments, and planned HQ build-out and surgical capacity spending will create near-term cash variability. That dynamic can constrain capital allocation choices and means execution must convert operating improvements into consistent positive FCF to finance growth without depleting reserves.
Execution And Regulatory Timing RiskKey product launches depend on 510(k) clearance and phased commercial rollouts, which introduce timing and execution risk. Delays or slow alpha launches compress near-term revenue contribution from new devices and postpone expected ASP/mix benefits tied to complementary offerings and reimbursement outcomes.
SI-Bone News
SIBN FAQ
What was SI-Bone Inc’s price range in the past 12 months?
SI-Bone Inc lowest stock price was $11.48 and its highest was $21.89 in the past 12 months.
What is SI-Bone Inc’s market cap?
SI-Bone Inc’s market cap is $787.64M.
When is SI-Bone Inc’s upcoming earnings report date?
SI-Bone Inc’s upcoming earnings report date is Nov 09, 2026 which is in 96 days.
How were SI-Bone Inc’s earnings last quarter?
SI-Bone Inc released its earnings results on Aug 03, 2026. The company reported -$0.09 earnings per share for the quarter, beating the consensus estimate of -$0.149 by $0.059.
Is SI-Bone Inc overvalued?
According to Wall Street analysts SI-Bone Inc’s price is currently Undervalued.
Does SI-Bone Inc pay dividends?
SI-Bone Inc does not currently pay dividends.
What is SI-Bone Inc’s EPS estimate?
SI-Bone Inc’s EPS estimate is -0.13.
How many shares outstanding does SI-Bone Inc have?
SI-Bone Inc has 44,349,280 shares outstanding.
What happened to SI-Bone Inc’s price movement after its last earnings report?
SI-Bone Inc reported an EPS of -$0.09 in its last earnings report, beating expectations of -$0.149. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of SI-Bone Inc?
Currently, no hedge funds are holding shares in SIBN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
SI-Bone Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$24.50 (47.41% Upside)
$24.50 (47.41% Upside)
Blogger Sentiment
Bullish
SIBN Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 741.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $507.6K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
54.93%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
7.72%
Trailing 12-Months
Company Description
SI-Bone Inc
SI-BONE, Inc. is a medical technology company that develops and markets specialized implantable solutions for musculoskeletal conditions affecting the sacropelvic region. These devices are utilized across the United States and internationally. Its flagship product, iFuse, is a minimally invasive surgical implant system designed to address a range of indications, including sacroiliac joint dysfunction and degeneration, adult spinal deformities, and traumatic fractures of the pelvic ring. Beyond iFuse, the company offers advanced iterations like iFuse-3D. This titanium implant retains the distinctive triangular cross-section of the original iFuse but incorporates a proprietary 3D-printed porous surface and a fenestrated design. Another offering is iFuse-TORQ, a series of 3D-printed threaded implants. These are specifically engineered for treating pelvic fractures and facilitating minimally invasive sacroiliac joint fusion procedures. SI-BONE distributes its products primarily through a dedicated direct sales force, complemented by a network of independent distributors. Established in 2008, the company maintains its corporate headquarters in Santa Clara, California.
SIBN Company Deck
SIBN Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong top-line growth, expanding physician adoption, robust gross margins, and meaningful improvement in adjusted EBITDA and cash balances. Management filed a 510(k) for a third breakthrough device, expects phased commercial launch in Q4, and benefited from favorable reimbursement actions (new DRGs and proposed SI joint increases). At the same time, the company remains modestly unprofitable on a GAAP basis, is investing in capacity and R&D which will cause near-term variability in cash flow and depreciation, and is taking a conservative view on near-term guidance due to seasonality and timing of catalysts. Overall, positives (growth, margin strength, reimbursement tailwinds, product pipeline and liquidity) outweigh near-term execution and timing risks.View all SIBN earnings summariesSIBN Stock 12 Month Forecast
Average Price Target
$24.50
▲(47.41% Upside)
Technical Analysis
Ownership Overview
5.15% Insiders
26.49% Mutual Funds
1.66% Other Institutional Investors
54.69% Public Companies and
Individual Investors